Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 plus low-dose aspirin versus aspirin 100 mg for platelet COX-1 inhibition in stable coronary heart disease
2016-004157-33Phase 2Terminated
- Sponsor
- Centro Cardiologico Monzino
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis comparing Cardioral with Cardioaspirin (2 arms). Primary endpoint: Platelet COX-1 inhibition efficacy. Started Jun 2021; status: terminated.
02
Drugs
Nipasaspirin
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2016-004157-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004157-33.